

# Diagnostic Accuracy of H. Pylori Fecal Antigen Test in Young Patients Presenting with Dyspepsia

Muhammad Aslam<sup>1</sup>, Waqas Shabbir<sup>2</sup>, Zubair Maqbool<sup>3</sup>, Muhammad Asim Hameed<sup>4</sup>, Kiran Namoos<sup>5</sup>

- 1** Senior Registrar, Department of Gastroenterology, Pakistan Kidney & Liver Institute (PKLI) And Research Centre, Lahore, Pakistan  
Conception & design, Manuscript writing
- 2** Assistant Professor, Department of Gastroenterology, Lahore General Hospital, Lahore, Pakistan  
Collection & assembly of data, Manuscript writing
- 3** Senior Registrar, Department of Gastroenterology, Lahore General Hospital, Lahore, Pakistan  
Results completing, Proof reading of manuscript
- 4** Assistant Professor, Department of Medicine, Lahore General Hospital, Lahore, Pakistan  
Literature search
- 5** Assistant Professor, Department of Biochemistry, Shalamar Medical & Dental College, Lahore, Pakistan  
Interpretation of data, Statistical analysis

## CORRESPONDING AUTHOR

Dr. Kiran Namoos

Assistant Professor, Department of Biochemistry,  
Shalamar Medical & Dental College, Lahore Pakistan  
Email: knamoos@hotmail.com

Submitted for Publication: 08-03-2021  
Accepted for Publication 24-04-2021

**How to Cite:** Aslam M, Shabbir W, Maqbool Z, Hameed MA, Namoos K. Diagnostic Accuracy of H. Pylori Fecal Antigen Test in Young Patients Presenting with Dyspepsia. APMC 2021;15(2):105-4. DOI: 10.29054/APMC/2021.1191

## ABSTRACT

**Background:** Eighty percent of the Pakistani population is suffering from gastric issues due to H. Pylori associated gastritis. **Objective:** To evaluate the diagnostic accuracy of HpSA test for H. Pylori infection in young patients presenting with dyspepsia taking standard Endoscopic Gastric Biopsy as gold standard. **Study Design:** Cross sectional study. **Settings:** Gastroenterology Department Lahore General Hospital, Lahore Pakistan. **Duration:** 7 months from 20<sup>th</sup> June to 19<sup>th</sup> December 2016. **Methodology:** A total 110 patients (18-35 years) with dyspepsia were included after taking approval from ethics committee of LGH/PGMI. After taking consent, fecal antigen detection test and gastric biopsies were carried out on all patient. Biopsy specimens were processed and observed. Hp stool antigen test was assessed from stool samples using ELISA technique. Diagnostic accuracy, sensitivity, specificity, positive predictive value and negative predictive value was measured by 2x2 contingency table. **Results:** A total of 60 patients (54.5%) had H.pylori infection as determined by gold standard biopsy whereas 76 (69.1%) patients were reported positive using fecal antigen. There was 83.3% sensitivity, 48.0% specificity, 65.8% positive predictive value, 70.6% negative predictive and 67.3% diagnostic accuracy. **Conclusion:** HpSA test has acceptable diagnostic accuracy in comparison with biopsy.

**Keywords:** Biopsy, H Pylori, Dyspepsia.

## INTRODUCTION

*Helicobacter pylori* (H. pylori) are gram negative bacteria and they were isolated in 1983 by Warren and Marshall.<sup>1</sup> This bacterium has been described in the pathogenesis of gastritis, peptic ulcer and gastric carcinoma. H.pylori induced gastritis is affecting almost half of the world population. Asia and Western Europe have the highest prevalence of H. pylori.<sup>2</sup> Contaminated water and fecal matter are the sources of contracting infection. The association of H. pylori is 80-90% with all the duodenal ulcers and about 80% with all the gastric ulcers.<sup>3</sup> *Helicobacter pylori* can be detected by invasive and non-invasive methods, based upon the need for endoscopy. Direct methods consist of microscopic demonstration of organism & indirect method is by using urease or response of antibody as an indicator of disease.<sup>4</sup> Preference of methods for test based upon price, accessibility, clinical condition, occurrence of infection and factors such as the use of PPI & antibiotics that may affect certain test outcomes.<sup>5</sup>

The biopsy urease test, culture & histology and phase contrast microscopy of gastric tissue need invasive endoscopy. But, urea breath test and stool antigen detection by EIA do not need invasive endoscopy.<sup>6</sup> Fecal antigen detection is a newer test and it is more precise than antibody testing and cheap than other available invasive and non-invasive tests. The specificity & sensitivity reported is 90% for fecal antigen detection in the various studies. As upper GI endoscopy is invasive procedure so H. pylori fecal antigen detection test can be used as alternative.<sup>7</sup> The aim of our study is to assess the diagnostic accuracy of H. Pylori infection in young patients presenting with dyspepsia taking standard Endoscopic Gastric Biopsy as gold standard.

## METHODOLOGY

**Study Design:** Cross sectional study.

**Settings:** Gastroenterology Department Lahore General Hospital, Lahore Pakistan.

**Duration:** 7 months from 20<sup>th</sup> June to 19<sup>th</sup> December 2016.

**Sample Technique:** Non-probability consecutive Sampling Technique.

**Sample Size:** The estimated sample size was 110 calculated by using 95% confidence level with an expected percentage of sensitivity as 90% with 7% margin of error, specificity 93% with 6 % margin of error of H Pylori fecal antigen test.<sup>8</sup>

**Inclusion Criteria:** Patients with age (18-35) years of either gender with dyspepsia (Postprandial fullness, early satiation, epigastric pain or burning) who were not responding to treatment after 4 weeks and reporting same symptoms, assessed on history and examination.

**Exclusion Criteria:** Patient with a history of alcoholism, history of either already diagnosed H. pylori infection or were previously treated for H. pylori and now who have presented with recurrence assessed from history and medical record. Patients with diagnosed pancreatitis, hepatitis C or hepatitis B, chronic liver disease of duration more than 5 years, malignancy, ischemic heart disease in the previous medical records.

**Data Collection Procedure:** Patients presenting with dyspepsia enrolled after taking approval from ethics committee of LGH/PGMI. A written consent was taken from all patients for participation in the study. All such patients who met the inclusion criteria were evaluated. Upper gastrointestinal endoscopy and fecal antigen detection test were done and gastric biopsies were taken. Biopsies were analyzed for histological examination. A patient was considered as H. pylori positive if the invasive tests was positive. Fecal antigen test was performed via lateral flow immuno-assay. Positive result was shown by pink red line appearing in the reading window after 5 minutes of incubation time.

**Data Analysis:** All data was analyzed using software i.e., SPSS version 20. Qualitative variables like gender, presence of H pylori infection on both tests i.e., fecal antigen test and gastric biopsy were measured as frequencies & percentages. Quantitative data like age, duration of symptoms was measured as means & standard deviation. Diagnostic accuracy, sensitivity, specificity, positive predictive value and negative predictive value was calculated by generating 2x2 contingency table. Diagnostic Accuracy is measured by this formula:  $TP+TN/TP+TN+FP+FN \times 100$ . Data was stratified for age, gender, duration of dyspepsia level to deal with effect modifiers.  $X^2$  test was used to calculate p value.

## RESULTS

Average age of 110 patients with dyspepsia was  $26.72 \pm 2.78$  years with most of the patients in the age range  $\geq 25$  years. Majority of the patients in the study were female (55.4%). Mean duration of disease was  $5.4 \pm 1.6$  months.

60 patients (54.5%) had H.pylori infection as determined by gold standard biopsy whereas 76 (69.1%) patients were reported positive using fecal antigen test.

Diagnostic accuracy was then calculated in terms of sensitivity, specificity, positive predictive value and negative predictive value using 2x2 table. Sensitivity, specificity, positive predictive value and negative predictive, diagnostic accuracy are 83.3%, 48.0%, 65.8%, 70.6%, 67.3% respectively.

**Table 1: Descriptive data of patients presented with dyspepsia**

Variables		No. of patient (n)%
Age (In years)	<25	52 (47.2%)
	$\geq 25$	58 (52.8%)
Gender	Male	49 (44.5%)
	Female	61 (55.4%)
Duration (In months)	<6 months	58 (52.7%)
	$\geq 6$ months	52 (47.3%)
H.Pylori Detection on Biopsy	Yes	60 (54.5%)
	No	50 (45.5%)
H.Pylori Detection on Fecal Antigen Test	Yes	76 (69.1%)
	No	34 (30.9%)

**Table 2: Diagnostic accuracy of fecal antigen test**

Fecal Antigen Test	Biopsy	
	Positive	Negative
Positive	50	26
Negative	10	24

Sensitivity: 83.3%

Specificity: 48.0%

Positive Predictive Value: 65.8%

Negative Predictive Value: 70.6%

Diagnostic Accuracy: 67.27%

**Table 3: Stratification of diagnostic accuracy of fecal antigen test with biopsy (n=110)**

Parameters		H. Pylori on Biopsy	H. Pylori on Fecal Antigen Test		Sensitivity	Specificity	+ve Predictive Value	-ve Predictive Value	p value
			Positive	Negative					
Age (years)	<25	Positive	19	9	67.9%	29.2%	52.8%	43.8%	0.81
		Negative	17	7					
		Total	36	16					
	≥25	Positive	22	10	68.8%	30.8%	55.0%	44.4%	0.96
		Negative	18	8					
		Total	40	18					
Gender	Male	Positive	19	8	70.4%	30.4%	54.3%	46.7%	0.95
		Negative	16	7					
		Total	35	15					
	Female	Positive	22	11	66.7%	29.6%	53.7%	42.1%	0.76
		Negative	19	8					
		Total	41	19					
Disease Duration (months)	≥6	Positive	19	9	67.9%	29.2%	52.8%	43.8%	0.81
		Negative	17	7					
		Total	36	16					
	<6	Positive	22	10	68.8%	30.8%	55.0%	44.4%	0.96
		Negative	18	8					
		Total	40	18					

## DISCUSSION

Our study showed that HpSA test has 83.3% sensitivity 48% specificity. The results are consistent with the study done by Syam AF *et al.*<sup>9</sup> We found high accuracy of HpSA test for the diagnosis of *H. pylori* infection in patients presenting with dyspepsia in current study. Another study done by Iannone A *et al.*, showed 95.9% diagnostic accuracy, 90.2% sensitivity and 98.5% specificity.<sup>10,11</sup> The mean age of patients presented with dyspepsia was 26.72 ± 2.78 years and 76 (69.1%) patients were positive for HpSA test. These results are similar to studies done by Eshraghian A *et al* and by Kazemi S *et al* who included young patients and there were 64% and 48% patients positive for HpSA test respectively.<sup>12,13,14</sup> Monoclonal stool antigen test, histology & urease test were used as a reference standard in few studies.<sup>15</sup> In one study histology and urea breath test was used as standard as compared to our study where standard was gastric biopsy.<sup>10,16</sup>

Tameshkel FS *et al.*, in his study showed that false negative results can occur because of mild Hp colonization in the gastric mucosa.<sup>17</sup> False positive results can also occur due to other *Helicobacter* species.<sup>18</sup> Stool sample condition may give false results as watery or unformed stool samples have diluted antigens so it gives less precise test results.<sup>19</sup> The HpSA test is fast and low-priced. In Pakistan, *H. Pylori* associated diseases are rising day by day so the findings of this study supported the use of non-invasive HpSA test.<sup>20</sup>

The accuracy of the stool antigen test was assessed in 270 patients in whom the diagnosis of *H. pylori* was recognized by endoscopy and UBT.<sup>21</sup> The results showed

94% sensitivity and 86% specificity of the test. Same findings were observed in a comparably designed study involving 272 infected patients.<sup>22</sup>

The stool antigen assay is also beneficial to judge either eradication has been effective or not.<sup>23</sup> In the study, the sensitivity and specificity for the test was 90 and 95 percent, respectively after four weeks of eradication therapy.<sup>24</sup> In similar study, the test was predictive of eradication as after seven days of completion of therapy.<sup>25</sup> However, few studies have noted a lower predictive accuracy of the tests in the situation of post-eradication testing and in cases of acute upper gastrointestinal bleeding.<sup>26</sup> In one, the test was falsely positive 32 % in whom *H. pylori* eradication was documented.<sup>24</sup> False-positive results have also been observed in patients with acute upper gastrointestinal bleeding due to cross-reactivity with blood constituents.<sup>27</sup> The main advantages of HpSA tests are less cost and easily performed with quick results as compared to the other tests. Moreover, these tests don't require expensive equipments.<sup>28</sup>

## CONCLUSION

HpSA test has acceptable diagnostic accuracy in comparison to gastric biopsy results.

## LIMITATIONS

Sample size is small. A single center study with a cross sectional design.

## SUGGESTIONS / RECOMMENDATIONS

Further studies with large sample size and multi centric approach may be more informative.

**CONFLICT OF INTEREST / DISCLOSURE**

There was no conflict of interest and nothing to disclosed in this research.

**ACKNOWLEDGEMENTS**

We acknowledge the services of staff of department of Gastroenterology who helped in collection of data.

**REFERENCES**

1. Wu H, Gu L, Ma X, Tian X, Fan S, Qin M, et al. Rapid Detection of *Helicobacter pylori* by the Naked Eye Using DNA Aptamers. *ACS Omega*. 2021;21.
2. Puculek M, Machlowska J, Wierzbicki R, Baj J, Maciejewski R, Sitarz R. *Helicobacter pylori* associated factors in the development of gastric cancer with special reference to the early-onset subtype. *Oncotarget*. 2018;9(57):31146.
3. Bayındır Bilman F, Özdemir M, Baysal B, Güzel Kurtoglu M. Prevalence of *H. pylori* in gastric biopsy specimen in the southeastern region of Turkey. *J Infect Dev Ctries*. 2016;10(11):1177-82.
4. Mohsun NE, al-Hadithi RH. The Role of ELISA test in the diagnosis of *Helicobacter pylori* infection. *J Faculty Med Baghdad*. 2011;53(3):311-3.
5. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of *Helicobacter pylori* Infection. *Am J Gastroenterol*. 2017;112(2):212-39.
6. Guevara B, Cogdill AG. *Helicobacter pylori*: A Review of Current Diagnostic and Management Strategies. *Dig Dis Sci*. 2020;65(7):1917-1931.
7. El-Shabrawi M, El-Aziz NA, El-Adly TZ, Hassanin F, Eskander A, Abou-Zekri M, Mansour H, Meshaal S. Stool antigen detection versus 13C-urea breath test for non-invasive diagnosis of pediatric *Helicobacter pylori* infection in a limited resource setting. *Arch Med Sci*. 2018;14(1):69-73.
8. Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, et al. Accuracy of rapid *Helicobacter pylori* antigen tests for the surveillance of the updated prevalence of *H. pylori* in Taiwan. *J Formos Med Assoc*. 2020;119(11):1626-1633.
9. Syam AF, Miftahussurur M, Makmun D, Nusi IA, Zain LH, Akil F, et al. Risk factors and prevalence of *Helicobacter pylori* in five largest islands of Indonesia: A preliminary study. *PloS one*. 2015;10(11):e0140186.
10. Iannone A, Giorgio F, Russo F, Riezzo G, Girardi B, Pricci M, et al. New fecal test for non-invasive *Helicobacter pylori* detection: A diagnostic accuracy study. *World J gastroenterol*. 2018;24(27):3021.
11. Giorgio F, Ierardi E, Sorrentino C, Principi M, Barone M, Losurdo G, et al. *Helicobacter pylori* DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. *Scand J Gastroenterol*. 2016;51(12):1429-1432.
12. Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, et al. Noninvasive molecular analysis of *Helicobacter pylori*: Is it time for tailored first-line therapy?. *World J gastroenterol*. 2017;23(14):2453.
13. Eshraghian A. Epidemiology of *Helicobacter pylori* infection among the healthy population in Iran and countries of the Eastern Mediterranean Region: a systematic review of prevalence and risk factors. *World J gastroenterol: WJG*. 2014;20(46):17618.
14. Kazemi S, Tavakkoli H, Habizadeh MR, Emami MH. Diagnostic values of *Helicobacter pylori* diagnostic tests: stool antigen test, urea breath test, rapid urease test, serology and histology. *J Res Med Sci*. 2011;16(9):1097-104.
15. Zhou X, Su J, Xu G, Zhang G. Accuracy of stool antigen test for the diagnosis of *Helicobacter pylori* infection in children: a meta-analysis. *Clin Res Hepatol Gastroenterol*. 2014;38(5):629-38.
16. Choi J, Kim CH, Kim D, Chung SJ, Song JH, Kang JM, Yang JI, Park MJ, Kim YS, Yim JY, Lim SH, Kim JS, Jung HC, Song IS. Prospective evaluation of a new stool antigen test for the detection of *Helicobacter pylori*, in comparison with histology, rapid urease test, (13)C-urea breath test, and serology. *J Gastroenterol Hepatol*. 2011;26(6):1053-9.
17. Safarnezhad Tameshkel F, Karbalaie Niya MH, Kheyri Z, Azizi D, Roozafzai F, Khorrami S. The Evaluation of Diagnostic and Predictive Values of *Helicobacter pylori* Stool Antigen Test in Iranian Patients with Dyspepsia. *Iran J Pathol*. 2018;13(1):38-44.
18. Liu J, He L, Haesebrouck F, Gong Y, Flahou B, Cao Q, et al. Prevalence of coinfection with gastric non-*Helicobacter pylori* *Helicobacter* (NHPH) species in *Helicobacter pylori*-infected patients suffering from gastric disease in Beijing, China. *Helicobacter*. 2015;20(4):284-90.
19. Rahimkhani M, Mordadi A, Kazemian K, Khalili H. Comparison of *Helicobacter pylori* Detection Methods: It's Association with Leukocytosis and Monocytosis. *Infect Disord Drug Targets*. 2020;20(6):920-924.
20. Tareen A, Butt T, Ali B. *Helicobacter pylori* infection in patients with chronic urticaria and dyspepsia, experience from a developing country. *J Pakistan Asso Dermatol*. 2017;26(3):206-13.
21. El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, et al. Houston Consensus Conference on Testing for *Helicobacter pylori* Infection in the United States. *Clin Gastroenterol Hepatol*. 2018;16(7):992-1002.
22. Somily AM, Morshed M. An update of laboratory diagnosis of *Helicobacter pylori* in the Kingdom of Saudi Arabia. *J Infect Dev Ctries*. 2015;9(08):806-14.
23. Gisbert JP, Calvet X. *Helicobacter Pylori* "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. *Clin Transl Gastroenterol*. 2013;4(3):e32.
24. Garza-González E, Perez-Perez GI, Maldonado-Garza HJ, Bosques-Padilla FJ. A review of *Helicobacter pylori* diagnosis, treatment, and methods to detect eradication. *World J Gastroenterol*. 2014;20(6):1438-49.
25. Gashau W, Adamu AS. Blind *Helicobacter pylori* Treatment in Dyspeptics in a High Prevalence Area. *Int J Cur Res Rev*. 2020;12(04):1.
26. Abdulkareem L. *Helicobacter pylori* infection among dyspeptic patients in the university of Abuja teaching hospital: prevalence and eradication rates. *Faculty of Internal Medicine*. 2015.
27. Das D, Abbas M, Akabar M, Nepal A, Islam MA, Ayuba A, et al. A clinical review on the pathology and management "Helicobacter pylori" infection. *Int J Adv Res Biol Sci*. 2016;3:18-30.
28. Korkmaz H, Kesli R, Karabagli P, Terzi Y. Comparison of the diagnostic accuracy of five different stool antigen tests for the diagnosis of *Helicobacter pylori* infection. *Helicobacter*. 2013;18(5):384-91.